Egyptian Pharmaceutical Journal

: 2016  |  Volume : 15  |  Issue : 2  |  Page : 62--69

Anticonvulsant potential of certain N-(6-substituted benzo[d] thiazol-2-yl)-2-(4-substituted piperazin-1-yl)acetamides

Ola Ahmed Saleh1, Mohamed Farrag El-Behery1, Mohamed Nabil Aboul-Enein1, Aida Abd El-Sattar El-Azzouny1, Yousreya Aly Maklad2,  
1 Pharmaceutical Chemistry Group, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (ID: 60014618), 33 El bohouth Street, Dokki-Giza, Egypt
2 Pharmacology Group, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (ID: 60014618), 33 El bohouth Street, Dokki-Giza, Egypt

Correspondence Address:
Mohamed Nabil Aboul-Enein
Pharmaceutical Chemistry Group, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (ID: 60014618), 33 El bohouth Street, Dokki-Giza


Background and objectives Epilepsy is a chronic neurological disorder. It is characterized by recurrent unprovoked occurrence of seizures that affect people of all ages. Thus, in the current work we undertook the synthesis of the joined structures of both 1, 3-benzothiazole and piperazine through amidic linkage, which will greatly foster the anticonvulsant profile of the new candidates. Experimental Synthesis of the target compounds N-(6-substituted benzo[d]thiazol-2-yl)-2-(4-substitued piperazinyl)acetamide derivatives (4a–f) was achieved. The anticonvulsant profile of these compounds at the selected dose of 100 mg/kg was investigated using maximal electroshock seizure and subcutaneous pentylenetetrazole screens as well as neurotoxicity test. Results and discussion Most of the synthesized compounds, 4a–f, displayed 16.67–100% anticonvulsant activity in maximal electroshock seizure screening at a dose range of 0.22–0.31 mmol/kg. The most potent compounds were 4a (ED50 = 58 mg/kg≡0.15 mmol/kg), 4b (ED50 = 64 mg/kg≡0.19 mmol/kg), and 4c (ED50 = 60 mg/kg≡0.19 mmol/kg). Compound 4a was the only one that exhibited 100% protection in the subcutaneous pentylenetetrazole screen with ED50 = 56 mg/kg≡0.15 mmol/kg. It possessed potent activity that was about six-fold more than that of ethosuximide (ED50 = 130 mg/kg≡0.92 mmol/kg), which was used as a reference drug, and lower than that of phenobarbital (ED50 = 13.20 mg/kg≡0.06 mmol/kg).

How to cite this article:
Saleh OA, El-Behery MF, Aboul-Enein MN, El-Azzouny AA, Maklad YA. Anticonvulsant potential of certain N-(6-substituted benzo[d] thiazol-2-yl)-2-(4-substituted piperazin-1-yl)acetamides.Egypt Pharmaceut J 2016;15:62-69

How to cite this URL:
Saleh OA, El-Behery MF, Aboul-Enein MN, El-Azzouny AA, Maklad YA. Anticonvulsant potential of certain N-(6-substituted benzo[d] thiazol-2-yl)-2-(4-substituted piperazin-1-yl)acetamides. Egypt Pharmaceut J [serial online] 2016 [cited 2021 Jul 23 ];15:62-69
Available from:

Full Text


Epilepsy, one of the oldest chronic neurological disorders, is characterized by fear, discrimination, and social manifestations. It is characterized by periodic and unpredictable occurrence of seizures and affects people of all ages [1]. The WHO, International Bureau for Epilepsy (IBE), and International League Against Epilepsy (ILAE) stated that 1% of the world's population is epileptic. Further, annually 2.4 million new cases are diagnosed with this disorder. Despite the adequacy of the current antiepileptic drugs, such as pregabalin, stiripentol, zonisamide, tiagabine, lamotrigine, levetiracetam, and topiramate, in seizure control, about 30% of patients are estimated to be poorly treated [2],[3]. These new drugs have demonstrated high efficacy in seizure control, although they are associated with some undesirable and painful side effects such as headache, nausea, hepatotoxicity, anorexia, ataxia, drowsiness, gastrointestinal disturbances, and hirsutism [4],[5]. That is why the search for new antiepileptic compounds with improved activity and lower toxicity continues to be an area of investigation in medicinal chemistry.

2-Aminobenzothiazole is a ubiquitous heterocyclic nucleus prevalent in many marine and natural plant products and has a varied range of biological applications[6],[7],[8],[9],[10],[11],[12]. Besides riluzole, which is a clinically available antiepileptic drug [13],[14],[15], many other 2-aminobenzothiazoles have been documented as very effective anticonvulsant agents [16],[17],[18],[19]. In contrast, piperazine is one of the most widely used heterocyclics for the development of new drug candidates. Its derivatives are driving versatile pharmacological activities [20],[21],[22],[23]. Also, many compounds containing piperazine scaffold are endowed with potent anticonvulsant activity [24],[25],[26],[27]. In addition, the amide moiety has been documented as a crucial pharmacophore in anticonvulsant activity [28]. Thus, in the current work we sought to synthesize the joint structures of both 1, 3-benzothiazole and piperazine through amidic linkage with the aim to foster the anticonvulsant profile of new candidates [Figure 1].{Figure 1}

 Materials and methods


All melting points were uncorrected and were determined with an electrothermal capillary melting point apparatus. Infrared (IR) spectra were recorded as thin film (for oils) in NaCl discs or as KBr pellets (for solids) using a JASCO FT/IR-6100 spectrometer, and values are represented in cm–1. 1H NMR and 13C NMR spectra were determined on a Jeol ECA 500 MHz spectrometer using Tetramethylsilane as internal standard, and chemical shift values were recorded in ppm on scale. The mass spectra were run on Finnigan Mat SSQ-7000 spectrometer and Jeol JMS-AX 500. Elemental analyses were carried out at the Microanalytical Unit, National Research Centre, Cairo, Egypt. Silica gel plates (60F254; Merck, Darmstadt, Germany) were used for thin-layer chromatography. Visualization was performed by illumination with UV light source (254 nm). Column chromatography was performed on silica gel 60 (0.063–0.200) purchased from Merck.

General synthetic procedure for 6-substituted benzothiazol-2-amine (2a-c)

A mixture of 0.1 mol of 4-substituted aniline and 0.1 mol of potassium thiocyanate in 100 ml glacial acetic acid was cooled in an ice bath and stirred for 10–20 min; thereafter, 0.1 mol bromine in glacial acetic acid was added dropwise at such a rate to keep the temperature below 10°C throughout the addition. The reaction mixture was stirred at room temperature for 2–4 h. The separated hydrobromide salt was filtered, washed with acetic acid, dried, dissolved in hot water, and neutralized with ammonia solution; and the resulting precipitate was filtered, washed with water, and dried to obtain the desired products 2a–c. The progress of the reaction was monitored by thin-layer chromatography using toluene: acetone (8: 2) solvent system. The physical characters and spectral data of 2a–c were in agreement with the reported data [17],[29].

6-Bromobenzo[d]thiazol-2-amine (2a)

Light yellow solid, yield: 76%, mp: 215–217°C (Lit. [29] mp: 216–219°C). IR (KBr, cm−1): 3448 (NH), 1526 (C = N). 1H NMR (CDCl3) δppm: 6.72 (s, 2H, NH2, D2O exchangeable), 7.39–7.46 (m, 2H, Har), 7.72 (d, J = 1.5 Hz, 1H, Har).

6-Chlorobenzo[d]thiazol-2-amine (2b)

White solid, yield: 72%, mp: 201–203°C (Lit. [29] mp: 202–203°C). IR (KBr, cm−1): 3341 (NH), 1544 (C = N); 1H NMR (CDCl3) δppm: 6.72 (s, 2H, NH2, D2O exchangeable), 7.21–7.35 (m, 2H, Har), 7.52 (d, J = 1.7 Hz, 1H, Har).

6-Methylbenzo[d]thiazol-2-amine (2c)

Light yellow solid, yield: 70%, mp: 144–146°C (Lit. [29] mp: 144–145°C). IR (KBr, cm−1): 3343 (NH), 1550 (C = N). 1H NMR (CDCl3) δppm: 1.96 (s, 3H, CH3), 5.89 (s, 2H, NH2, D2O exchangeable),7.53–7.39 (m, 3H, Har).

General synthetic procedure for 2-chloro-N-(6-substituted benzo[d]thiazol-2-yl) acetamides (3a–c)

Chloroacetyl chloride (0.06 mol) was added dropwise to a mixture of the appropriate 2-amino-6-substituted benzo[d]thiazole (2a–c) (0.05 mol) and K2CO3 (0.06 mol) in benzene (50 ml) at room temperature. The reaction mixture was refluxed for 6–12 h.

After cooling to room temperature, it was slowly poured into 100 ml of ice cold water. A solid was formed thereafter. The precipitate was separated by filtration and washed successively with water. The product was dried under vacuum to obtain 3a–c.

The progress of the reaction was monitored by thin-layer chromatography using the toluene: acetone (8: 2) solvent system.

The physical characters and spectral data of 3a–c were in agreement with the reported data [29],[30],[31],[32].

2-Chloro-N-(6-bromobenzo[d]thiazol-2-yl)acetamide (3a)

Light yellow solid, yield: 72%, mp: 194–196°C (Lit. [29] mp: 195–197°C). IR (KBr, cm−1): 3275 (NH), 1667 (C = O). 1H NMR (CDCl3) δppm: 4.06 (s, 2H, -CH2-Cl), 7.35–7.43 (m, 2H, Har), 7.60 (d, J = 1.7 Hz, 1H, Har), 8.43 (s, 1H, -NH); MS (EI) m/z (%): 305.58 (40) (M++1), 228 (100).

2-Chloro-N-(6-chlorobenzo[d]thiazol-2-yl)acetamide (3b)

While solid, yield: 71%, mp: 207–209°C (Lit. [29] mp: 207–210°C). IR (KBr, cm−1): 3271 (NH), 1666 (C = O); 1H NMR (CDCl3) δppm: 4.17 (s, 2H, -CH2-Cl), 7.27–7.45 (m, 2H, Har), 7.64 (d, J = 1.6 Hz, 1H, Har), 8.56 (s, 1H,-NH). MS (EI) m/z (%): 262.03 (20) (M+ + 1), 260.03 (40), 184.08 (100).

2-Chloro-N-(6-methylbenzo[d]thiazol-2-yl)acetamide (3c)

Light yellow solid, yield: 53%, mp: 174–176 (Lit. [29] 175–177°C). IR (KBr, cm−1): 3291 (NH), 1670 (C = O). 1H NMR (CDCl3) δppm: 1.81 (s, 3H, CH3), 4.20 (s, 2H,-CH2-Cl), 7.63–7.46 (m, 3H, Har), 8.45 (s, 1H, NH). MS (EI) m/z (%): 239.5 (60) (M+), 164.11 (100).

General procedure for the synthesis of N-(6-substituted benzothiazol-2-yl)-2-(4- substituted piperazin-1-yl)acetamides (4a–f)

Method 1: A mixture of 0.0025 mol of 2-chloro-N-(6-substituted benzo [d]thiazol-2-yl) acetamides (3a–c) and 0.0025 mol of the suitable piperazine derivative in acetone (50 ml), in the presence of 0.0025 mol anhydrous K2CO3, was refluxed for 18 h. The reaction was monitored by thin-layer chromatography with silica gel plate and benzene: methanol (9: 1) mobile phase mixture. Potassium carbonate was removed by filtration. After evaporation of acetone, the precipitated products were recrystallized from absolute ethanol or acetone: distilled water mixture to afford 4a–d in 30–41% yields.

Method 2: To a solution of 0.003 mol of 2-chloro-N-(6-chloro- or 6-methyl-benzo[d]thiazol-2-yl) acetamides (3b or 3c) and 0.004 mol of benzyl piperazine hydrochloride in Dimethylformamide (DMF) (15 ml) was added six drops of triethylamine. The reaction mixture was refluxed for 6 h, then diluted with H2O (20 ml), and stirred at room temperature for 12 h. The solid was filtrated and recrystallized from absolute ethanol to afford 4e or 4f in 39% yields.

N-(6-Bromobenzo[d]thiazol-2-yl)-2-(4-ethylpiperazin-1-yl)acetamide (4a)

Yellow solid, yield: 35%, mp: 146–150°C. IR (KBr, cm−1): 3287 (NH), 1702 (C = O); 1H NMR (CDCl3) δppm: 1.05–1.13 (t, J = 7.1 Hz, 3H, CH3), 2.42–2.57 (m, 10H, CH2-CH3, 4 × CH2 piperazinyl), 3.31 (s, 2H, O = C-CH2-N), 7.26–7.74 (m, 3H, Har), 10.41 (br.s., 1H, NH); 13C NMR (CDCl3) δppm: 12.05 (CH3), 52.48, 52.66, 53.76 (CH3-CH2, 4 × CH2 piperazinyl), 61.30 (O = C-CH2-N), 121.18, 121.90, 127.08, 129.64 (3 × CH ar,1 × Car), 133.60 (Car), 147.17 (Car -N), 157.71 (C = O), 169.40 (N = C-S, thiazolyl); MS (EI) m/z (%): 383 (5) (M+ + 1), 228 (10), 127 (100); Anal. Calcd. for C15H19Br N4OS: C, 47.00; H, 5.00; N,14.62. Found: C, 47.09; H, 5.05; N, 14.60.

N-(6-Chlorobenzo[d]thiazol-2-yl)-2-(4-ethylpiperazin-1-yl)acetamide (4b)

Light yellow solid, yield: 31%, mp: 176–180°C; IR (KBr, cm−1): 3266 (NH), 1702 (C = O); 1H NMR (CDCl3) δppm: 1.08–1.11 (t, J = 7.1 Hz, 3H, CH3), 2.45–2.68 (m, 10H, CH2-CH3, 4 × CH2 piperazinyl), 3.28 (s, 2H, O = C-CH2-N), 7.37–7.77 (m, 3H, Har), 10.39 (br.s., 1H, NH); 13C NMR (CDCl3) δppm: 12.01 (CH3), 52.28, 52.64, 53.72 (CH3-CH2, 4 × CH2 piperazinyl), 61.10 (O = C-CH2-N), 121.18, 121.90, 127.08, 129.64 (3 × CH ar,1 × Car), 133.60 (Car), 147.17 (Car -N), 157.51 (C = O), 169.39 (N = C-S, thiazolyl); MS (EI) m/z (%): 338.5 (10) (M+), 211.02 (8), 184.03 (9), 127 (100); Anal. Calcd. for C15H19Cl N4OS: C, 53.17; H, 5.65; N,16.53. Found: C, 53.20; H, 5.69; N, 16.60.

2-(4-Ethylpiperazin-1-yl)-N-(6-methylbenzo[d]thiazol-2-yl)acetamide (4c)

Yellow white solid, yield: 30%, mp: 98–102°C. IR (KBr, cm−1): 3430 (NH), 1701 (C = O); 1H NMR (CDCl3) δppm: 1.08–1.11 (t, J = 7.1 Hz, 3H, CH3-CH2), 2.45–2.68 (m, 13H, CH2-CH3, CH3-Car, 4 × CH2 piperazinyl), 3.37 (s, 2H, O = C-CH2-N), 7.23–7.66 (m, 3H, Har), 10.40 (br. s., 1H, NH); 13C NMR (CDCl3) δppm: 11.99 (CH3-CH2), 21.58 (CH3-Car) 52.28, 52.64, 53.70 (CH3-CH2, 4 × CH2 piperazinyl), 61.19 (O = C-CH2-N),120.63, 121.34, 127.86 (3 × CHar), 132.44, 134.17 (2 × Car), 146.46 (Car- N), 156.47 (C = O), 169.20 (N = C-S, thiazolyl); MS (EI) m/z (%): 319 (10) (M+ + 1), 205 (4), 191 (27), 163 (30); Anal. Calcd. for C16H22N4OS: C, 60.35; H, 6.96; N,17.59. Found: C, 60.30; H, 6.89; N, 17.62.

2-(4-Benzylpiperazin-1-yl)-N-(6-bromobenzo[d]thiazol-2-yl)acetamide (4d)

Yellow solid, yield: 41%, mp: 197–200°C. IR (KBr, cm−1): 3292 (NH), 1706 (C = O); 1H NMR (CDCl3) δppm: 2.56 (t, J = 5.4 Hz, 4H, 2 × CH2, piperazinyl), 2.66 (t, J = 4.8 Hz, 4H, 2 × CH2, piperazinyl), 3.27 (s, 2H, O = C-CH2-N), 3.54 (s, 2H. CH2-Ph), 7.25–7.32 (m, 5H, Har), 7.63–7.93 (m, 3H, Har), 10.49 (br.s., 1H, NH); 13C NMR (CDCl3) δppm: 52.93, 53.81 (4 × CH2 piperazinyl), 61.12 (O = C-CH2-N), 62.95 (CH2-Ph), 117.09 (Car), 122.31, 124.07, 127.35, 128,42, 129.26, 129.80 (8 × CHar), 134.09 (Car), 137.80 (Car), 147.52 (Car), 157.54 (C = O), 169.52 (N = C-S, thiazolyl); MS (EI) m/z (%): 444 (100) (M+), 353 (10), 91 (100); Anal. Calcd. for C20H21BrN4OS: C, 53.94; H, 4.75; N, 12.58. Found: C, 53.91; H, 4.79; N, 12.60.

2-(4-Benzylpiperazin-1-yl)-N-(6-chlorobenzo[d]thiazol-2-yl)acetamide (4e)

Light yellow solid, yield: 39%, mp: 118–120°C; IR (KBr, cm−1): 3264 (NH), 1705 (C = O); 1H NMR (CDCl3) δppm: 2.56 (t, J = 5.4 Hz 4H, 2 × CH2, piperazinyl), 2.66 (t, J = 4.8 Hz, 4H, 2 × CH2, piperazinyl), 3.28 (s, 2H, O = C-CH2-N), 3.54 (s, 2H. CH2-Ph), 7.25–7.32 (m, 5H, CHar), 7.63–7.93 (m, 3H, CHar), 10.49 (br.s., 1H, NH); 13C NMR (CDCl3) δppm: 52.90, 53.77 (4 × CH2 piperazinyl), 61.11 (O = C-CH2-N), 62.93 (CH2-Ph), 121.18 (Car), 121.90, 127.09, 127.38, 128,44, 129.29, 129.64 (8 × CHar), 133.58 (Car), 137.70 (Car), 147.16 (Car), 157.56 (C = O), 169.51 (N = C-S, thiazolyl); MS (EI) m/z (%): 400.23 (5) (M+), 309.06 (3), 189.18 (15), 91 (100); Anal. Calcd. for C20H21ClN4OS: C, 59.91; H, 5.28; N, 13.97. Found: C, 59.79; H, 5.30; N, 13.99.

2-(4-Benzylpiperazin-1-yl)-N-(6-methylbenzo[d]thiazol-2-yl)acetamide (4f)

Light yellow solid, yield: 39%, mp: 100–104°C. IR (KBr, cm−1): 3254 (NH), 1706 (C = O); 1H NMR (CDCl3) δppm: 2.26–2.75 (m, 11H, CH3-Car, 4 × CH2 piperazinyl), 3.26 (s, 2H, O = C-CH2-N), 3.54 (s, 2H. CH2-Ph), 7.24–7.31 (m, 5H, Har), 7.32–7.59 (m, 3H, Har), 10.46 (br.s.,1H, NH); 13C NMR (CDCl3) δppm: 21.59 (CH3), 52.93, 53.77 (4 × CH2 piperazinyl), 61.19 (O = C-CH2-N), 62.97 (CH2-Ph), 120.64, 121.35, 127.34, 127.49,127.87,128.42,129.31, 132.44 (8 × CHar, 1 × Car), 134.17, 137.77 (2 × Car), 146.44 (Car-N), 156.48 (C = O), 169.31 (N = C-S, thiazolyl); MS (EI) m/z (%): 381 (25) (M+ + 1), 290.28 (20), 189.30 (30), 191.25 (100); Anal. Calcd. for C21H24N4OS: C, 66.29; H, 6.36; N, 14.72. Found: C, 66.34; H, 6.39; N, 14.70.

 Materials and methods



Adult male albino mice (18–25 g) were used in this study. The animals were purchased from the Animal House Colony of the National Research Centre, Cairo, Egypt and housed under standardized conditions of room temperature (23 ± C), relative humidity (55 ± 5%), and light (12-h light/dark cycle) and had free access to tap water as well as standard mice chow throughout the experimental period. The procedures on animals, and their care, were performed as per the guidelines of the Ethics Committee of the National Research Centre and the ‘Canadian Council on Animal Care Guidelines 1984’. All efforts were made to minimize the suffering of animals and to use only the number of animals necessary to produce reliable data.

Drugs and chemicals

Diphenylhydantoin (Nasr Co., Giza, Egypt), ethosuximide (Pfizer Co., Giza, Egypt), phenobarbital (Memphis Co. for Pharmaceutical and Chemical Industries, Cairo, Egypt), pentylenetetrazole, and Tween 80 (Sigma, St Louis, Missouri, USA) were used. The reference drugs and tested compounds were administered intraperitoneally at a volume of 0.1 ml/10 g body weight.


Animals were adapted to laboratory conditions for 7 days. They were then randomly assigned to control, reference, and tested groups consisting of six mice each. Every animal was used once. All tested compounds were suspended in 7% Tween 80.

Maximal electroshock seizure screen [33]

The reference group of animals received diphenylhydantoin (45 mg/kg, 0.16 mmol/kg) as the reference drug. A second group received the vehicle and served as the control group. Other groups received the test compounds individually by intraperitoneal injection at a dose level equivalent to 100 mg/kg [34].

Thirty minutes later electroconvulsions were induced through a current (fixed intensity of 25 mA, 0.2 s stimulus duration) delivered through a ear-clip electrode by means of a Rodent Shocker Generator (Type 221; Hugo Sachs Elektronik, Freiburg, Germany). The maximal seizures characterized by a short period of initial tonic flexion and a prolonged period of tonic extension followed by terminal clonus lasted ∼22 s. Failure to extend the hind limbs to an angle with the trunk greater than 90° was considered as indicating protection [35].

Subcutaneous pentylenetetrazole-induced seizures screen [36]

The control group of mice was treated with the solvent alone. Meanwhile, the other groups received (intraperitoneal) the reference drugs ethosuximide (150 mg/kg–1.06 mmol/kg), phenobarbital (30 mg/kg–0.13 mmol/kg), or one of the compounds under investigation. Thirty minutes later, pentylenetetrazole was administered subcutaneously in the loose folds of the skin on the back of the neck at a dose of 85 mg/kg [37]. Each animal was observed for 30 min. Failure to observe a threshold seizure (a single episode of clonic spasm of at least 5 s duration) was defined as protection [38].

Neurotoxicity [39]

Neurotoxicity was tested with the rotarod test, which is designed to detect minimal neurological defect. In this test, the animals were trained to maintain equilibrium on a rotating 1-inch-diameter knurled plastic rod at a speed of 6 rpm for at least 1 min in each of three trials using a rotarod device (UGD Basile, Varese, Italy). Only animals that fulfilled this criterion were included in the experiment. The selected animals were then divided between the control group, in which the mice received the vehicle, and the experimental groups, in which the mice received (intraperitoneal) one of the test compounds (in mmol/kg–100 mg/kg in 7% aqueous suspension of Tween 80). Thirty minutes later, the mice were placed again on the rotating rod and the motor performance time was recorded up to 60 s. The neurotoxicity was indicated by the inability of the animal to maintain equilibrium on the rod for at least 60 s.

Median effective dose (ED50)

ED50 was the dose of the drug required to produce the desired biological response in 50% of animals. Groups of eight mice each were given a range of intraperitoneal doses of the test compound until at least three points were established in the range of 15–84% seizure protection. From the plot of these data, the respective ED50 value and the confidence limits were calculated [40].

 Results and discussion


Synthesis of the compounds N-(6-substituted benzothiazol-2-yl)-2-(4-substituted piperazinyl)acetamide derivatives (4a–f) is outlined in Scheme 1. The target compounds were obtained through three stages: first, the substituted 2-amino-benzothiazole derivatives 2a–c were formed by treating the appropriate substituted anilines 1a–c with potassium thiocyanate and bromine in acetic acid according to the reported procedure [17],[29]. Thereafter, the amines 2a–c were chloroacetylated in the presence of anhydrous potassium carbonate in benzene to achieve the respective compounds 3a–c in good yields as described in the literature [30],[31],[32]. Reaction of the chloroacetylated compounds 3a–c and ethyl or benzyl piperazine hydrochlorides under basic conditions using anhydrous potassium carbonate or triethylamine in acetone or DMF (Methods 1 and 2, respectively) afforded the target compounds 4a–f in 30–41% yields (c.f. experimental).


The compounds under investigation were subjected to preliminary anticonvulsant screening according to the standard procedure adopted by the Antiepileptic Drug Development (ADD) program [41], which includes the ‘gold standard’ screens in the early stages of testing (phase 1). These include the following: (a) the maximal electroshock seizure (MES) screen that is indicative of the ability of the test compounds to prevent seizure spreading; and (b) the subcutaneous pentylenetetrazole (sc PTZ) screen that identifies compounds that elevate the seizure threshold. Compounds that exhibited 100% protection against the induced seizures were subjected to median effective dose (ED50) evaluation as well as estimation of the minimal motor impairment (neurotoxicity).

The anticonvulsant activity expressed as % protection of the test compounds N-(6-substitutedbenzothiazol-2-yl)-2-(4-substitued piperazinyl)acetamide derivatives (4a–f) as well as their neurotoxicity is presented in [Table 1]. The initial anticonvulsant evaluation indicated that all the tested compounds were effective in intraperitoneal MES and sc PTZ screens as the new entities showed protection in the range of 16.67–100% at the tested dose level equivalent to 100 mg/kg after 30 min from compound administration.{Table 1}

In the MES screen the obtained data indicated the ability of the tested compounds to protect mice from seizure spreading. Compounds 4a, 4b, and 4c were the most potent congeners as they exhibited 100% protection against maximal electric shock at dose levels of 0.26, 0.29, and 0.31 mmol/kg (–100 mg/kg), respectively. Meanwhile, diphenylhydantoin used as a reference drug exhibited 100% protection at a dose level of 0.16 mmol/kg (–45 mg/kg).

In the sc PTZ screen, compound 4a at a dose of 0.26 mmol/kg (–100 mg/kg) was the most potent congener as it exhibited 100% protection against sc PTZ-induced seizures in mice. Meanwhile, the reference drugs phenobarbital and ethosuximide exhibited 100% protection at dose levels of 0.13 and 1.06 mmol/kg, respectively. Compounds 4b (0.29 mmol/kg) and 4f (0.26 mmol/kg) exhibited equipotent activity of 50% protection at the tested dose levels (equivalent to 100 mg/kg).

With regard to the neurotoxicity, acute toxicity from antiepileptic drugs in rodents is shown by neurological deficits, which include ataxia, sedation, impaired righting reflexes, and altered motor activity, collectively are termed ‘neurotoxicity’. The standardized test, the rotarod test, can detect the minimal neurological defect, such as impaired motor function [42]. Compounds that exhibited 100% protection in MES and/or sc PTZ screens were subjected to neurotoxicity estimation as well as ED50 evaluation.

Results of the neurotoxicity test [Table 1] revealed that compounds 4d and 4e were devoid of neurotoxicity. On the other hand, compounds 4a and 4f exhibited minimal neurotoxicity. Meanwhile, compounds 4b and 4c showed moderate toxicity at the tested dose. [Table 2] shows the ED50 of the selected compounds. Compound 4a gave an ED50 of 58 mg/kg (–0.15 mmol/kg) in the MES screen. Moreover, in the sc PTZ screen, only compound 4a showed 100% protection against the induced seizures with ED50 = 56 mg/kg (–0.15 mmol/kg), about six-fold more potent than that of the reference drug ethosuximide (ED50 = 130 mg/kg–0.92 mmol/kg). Meanwhile, it had lower potency than that of phenobarbital (ED50 = 13.20 mg/kg–0.06 mmol/kg).{Table 2}

From the present results we can deduce that compound 4a was the most potent congener as it exhibited 100% protection against both MES and sc PTZ-induced seizures with minimal neurotoxicity. Meanwhile, compounds 4b and 4c exhibited 100% protection against MES-induced seizures only and demonstrated moderate neurotoxicity. It was observed from the MES screen that the 4-ethyl piperazine derivatives 4a (ED50 = 58 mg/kg–0.15 mmol/kg), 4b (ED50 = 64 mg/kg–0.19 mmol/kg), and 4c (ED50 = 60 mg/kg–0.19 mmol/kg) were the most active congeners, whereas substituting the 4-ethyl piperazine with 4-benzyl piperazine as in compounds 4d, 4e, and 4f decreased the anticonvulsant activity.


Synthesis and determination of the anticonvulsant potential of certain N-(6-substitutedbenzo[d]thiazol-2-yl)-2-(4-substitued piperazinyl)acetamide derivatives (4a–f) were undertaken. Most of the compounds displayed 16.67–100% anticonvulsant activity in the MES screen at a dose range of 0.22–0.31 mmol/kg. The most potent compounds were 4a (ED50 = 58 mg/kg–0.15 mmol/kg), 4b (ED50 = 64 mg/kg–0.19 mmol/kg), and 4c (ED50 = 60 mg/kg–0.19 mmol/kg). Compound 4a was the only one that displayed 100% protection in the sc PTZ screen with ED50 = 56 mg/kg (–0.15 mmol/kg). It possessed potent activity that was about six-fold more than that of ethosuximide (ED50 = 130 mg/kg–0.92 mmol/kg) and lower than that of phenobarbital (ED50 = 13.20 mg/kg–0.06 mmol/kg), which were used as reference drugs.

Conflicts of interest

The authors declared that there is no conflict of interest.


1Fisher R, Boas WVE, Blume W, Elger C, Genton P, Lee P, Engel J. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46:470–472.
2Yogeeswari P, Sriram D, Thirumurugan R, Raghavendran JV, Sudhan K, Pavana RK, Stables J. Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design. J Med Chem 2005; 48:6202–6211.
3Meador KJ. Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. J Clin Psychiatry 2003; 64:30–34.
4Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004; 61:1–48.
5Wolfe JF, Greenwood TD, Mulheron JM. Recent trends in the development of new anti-epileptic drugs. Expert Opin Ther Patents 1998; 8:361–381.
6Ibrahim DA, Lasheen DS, Zaky MY, Ibrahim AW, Vullo D, Ceruso M et al. Design and synthesis of benzothiazole-6-sulfonamides acting as highly potent inhibitors of carbonic anhydrase isoforms I, II, IX and XII. Bioorg Med Chem 2015; 23:4989–4999.
7Romani D, Brandán SA. Structural and spectroscopic studies of two 1,3-benzothiazole tautomers with potential antimicrobial activity in different media. Comput Theor Chem 2015; 1061:89–99.
8Ma J, Bao G, Wang L, Li W, Xu B, Du B et al. Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents. Eur J Med Chem 2015; 96:173–186.
9Apelt J, Grassmann S, Ligneau X, Pertz HH, Ganellin CR, Arrang JM et al. Search for histamine H3 receptor antagonists with combined inhibitory potency at N(-methyltransferase: ether derivatives. Pharmazie 2005; 60:97–106.
10Akhtar T, Hameed S, Al-Masoudi NA, Loddo R, Colla PL. In vitro antitumor and antiviral activities of new benzothiazole and 1,3,4-oxadiazole-2-thione derivatives. Acta Pharm 2008; 58:135–149.
11Keri RS, Patil MR, Patil SA, Budagumpi S. A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. Eur J Med Chem 2015; 89:207–251.
12Gurdal EE, Durmaz I, Cetin-Atalay R, Yarim M. Cytotoxic activities of some benzothiazol-piperazine derivatives. J Enzyme Inhib Med Chem 2015; 30:649–654.
13Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007; 32:793–802.
14De Sarro G, Siniscalchi A, Ferreri G, Gallelli L, De Sarro A. NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. Eur J Pharmacol 2000; 408:25–34.
15Romettino S, Lazdunski M, Gottesmann C. Anticonvulsant and sleep-waking influences of riluzole in a rat model of absence epilepsy. Eur J Pharmacol 1991; 199:371–373.
16Ugale VG, Patel HM, Wadodkar SG, Bari SB, Shirkhedkar AA, Surana SJ. Quinazolino–benzothiazoles: fused pharmacophores as anticonvulsant agents. Eur J Med Chem 2012; 53:107–113.
17Rana A, Siddiqui N, Khan SA, Ehtaishamul Haque S, Bhat MA. N-{[(6-Substituted-1,3-benzothiazole-2-yl)amino]carbonothioyl}-2/4-substituted benzamides: synthesis and pharmacological evaluation. Eur J Med Chem 2008; 43:1114–1122.
18Hassan MZ, Khan SA, Amir M. Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl) amides as anticonvulsant and neuroprotective. Eur J Med Chem 2012; 58:206–213.
19Jimonet P, Audiau F, Barreau M, Blanchard JC, Boireau A, Bour Y et al. Riluzole series. Synthesis and in vivo’ antiglutamate’ activity of 6- substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem 1999; 42:2828–2843.
20Akkoç MK, Yüksel MY, Durmaz I, Atalay RE. Design, synthesis, and biological evaluation of indole-based 1,4-disubstituted piperazines as cytotoxic agents. Turk J Chem 2012; 36:515–525.
21Joshi NK, Kundariya DS, Parmar JM. Synthesis, characterization and anti-microbial evaluation of some novel 1,3,4-oxadiazoles containing piperazine moiety. Int J Chem Tech Res 2012; 4:1503–1508.
22Ibezim E, Duchowicz PR, Ortiz EV, Castro EA. QSAR on aryl-piperazine derivatives with activity on malaria. Chemo Metr Intell Lab 2012; 110:81–88.
23Cho SD, Song SY, Kim KH, Zhao BX, Ahn C, Joo WH et al. One-pot synthesis of symmetrical 1,4-disubstituted piperazine-2,5-diones. Bull Korean Chem Soc 2004; 25:415–416.
24Waszkielewicz AM, Gunia A, Szkaradek N, Pytka K, Siwek A, Satała G et al. Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety. Bioorg Med Chem Lett 2013; 23:4419–4423.
25Kumari S, Mishra CB, Tiwari M. Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents. Bioorg Med Chem Lett 2015; 25:1092–1099.
26Chapman AG, Hart GP, Meldrum BS, Turski L, Watkins JC. Anticonvulsant activity of two novel piperazine derivatives with potent kainate antagonist activity. Neurosci Lett 1985; 55:325–330.
27Kamiński K, Rzepka S, Obniska J. Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin- 1-yl)ethyl]pyrrolidine-2,5-diones. Bioorg Med Chem Lett 2011; 21:5800–5803.
28Aboul-Enein MN, El-Azzouny AA, Attia MI, Maklad YA, Amin KM, Abdel-Rehim M, El-Behairy MF. Design and synthesis of novel stiripentol analogues as potential anticonvulsants. Eur J Med Chem 2012; 47:360–369.
29Patel RV, Patel PK, Kumari P, Rajani DP, Chikhalia KH. Synthesis of benzimidazolyl-1,3,4-oxadiazol-2ylthio-N-phenyl (benzothiazolyl) acetamides as antibacterial, antifungal and antituberculosis agents. Eur J Med Chem 2012; 53:41–51.
30Turan-Zitouni G, Demirayak S, Ozdemir A, Kaplancikli ZA, Yildiz MT. Synthesis of some 2-[(benzazole-2-yl)thioacetylamino]thiazole derivatives and their antimicrobial activity and toxicity. Eur J Med Chem 2004; 39:267–272.
31Amin KM, Rahman DEA, Al-Eryani YA. Synthesis and preliminary evaluation of some substituted coumarins as anticonvulsant agents. Bioorg Med Chem 2008; 16:5377–5388.
32Wang M, Gao M, Mock BH, Miller KD, Sledge GW, Hutchinsa GD, Zhenga QH. Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents. Bioorg Med Chem 2006; 14:8599–8607.
33Luszczki JJ, Czuczwar M, Gawlik P, Sawiniec-Pozniak G, Czuczwar K, Czuczwar SJ. 7-Nitroindazole potentiates the anticonvulsant action of some second-generation antiepileptic drugs in the mouse maximal electroshock-induced seizure model. J Neural Transm 2006; 113:1157–1168.
34El-Behairy MF, Aboul-Enein MN, El-Azzouny AA, Saleh OA, Maklad YA, Aboutabl ME, Maghraby AS. Design, synthesis, and biological profile of novel N-(5-aryl-1,3,4-thiadiazol-2-yl) hydrazinecarboxamides. Eur J Chem 2014; 5:488–496.
35Swinyard EA, Brown WC, Goodman LS. Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 1952; 106:319–330.
36Clark CR, Wells MJ, Sansom RT, Norris GN, Dockens RC, Ravis WR. Anticonvulsant activity of some 4-aminobenzamides. J Med Chem 1984; 27:779–782.
37Fariello RG, McArthur RA, Bonsignori A, Cervini MA, Maj R, Marrari P et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharm Exp Therap 1998; 285:397–403.
38Alam O, Mullick P, Verma SP, Gilani SJ, Khan SA, Siddiqui N, Ashsan W. Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives. Eur J Med Chem 2010; 45:2467–2472.
39Sun XY, Jin YZ, Li FN, Li G, Chai KY, Quan ZS. Synthesis of 8-alloxy-4,5-dihydro[1,2,4] triazole [4,3-a]quinoline-1-ones and evaluation of their anticonvulsant properties, Arch. Pharm Res 2006; 29:1080–1085.
40Litchfield JT, Wilcoxon FAJr. A simplified method of evaluating dose–effect experiments. J Pharmacol Exp Ther 1949; 96:99–113.
41Porter RJ, Cereghino JJ, Gladding GD, Hessie BJ, Kuprferberg HJ, Scoville B, White BG. Antiepileptic drug development program. Clev Clin Q 1984; 51:293–305.
42Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. Am Pharm Assoc 1957; 46:208–209.